Hematological inflammation coefficients as predictors of QT interval prolongation during clozapine therapy

Hematological inflammation coefficients as predictors of QT interval prolongation during clozapine therapy

 

Authors

 

A.V. Kidyaeva

Federal State Budgetary Institution “V.M. Bekhterev National Medical Research Center for Psychiatry and Neurology” of the Ministry of Health of the Russian Federation, Institute of Personalized Psychiatry and Neurology, St. Petersburg, Russian Federation

R.F. Nasyrova

Federal State Budgetary Institution “V.M. Bekhterev National Medical Research Center for Psychiatry and Neurology” of the Ministry of Health of the Russian Federation, Institute of Personalized Psychiatry and Neurology, St. Petersburg, Russian Federation

 

https://doi.org/10.26617/1810-3111-2025-2(127)-62-69

 

Journal: Siberian Herald of Psychiatry and Addiction Psychiatry. 2025; 2 (127):  62-69.

 

Abstract

Background. According to the literature, more than two thirds of patients with schizophrenia die from cardiovascular diseases. Among the agents of drug therapy for schizophrenia, preference is given to antipsychotic drugs. Prolongation of the QT interval as a prognostic marker of fatal rhythm disturbances is one of the most significant adverse reactions associated with the use of antipsychotics due to the high risk of life-threatening arrhythmias. Objective: to determine the relationship between clinical and laboratory parameters and prolongation of the QTc interval in patients with schizophrenia taking clozapine. Materials and Methods. The study included 129 inpatients with an established diagnosis according to ICD-10: paranoid schizophrenia (F20.0), receiving clozapine therapy. Prolongation of the QTc interval was defined as a difference of ≥30 ms between the QTc interval values of the repeated and baseline electrocardiograms. Results.An increased risk of QTc interval prolongation was found with a statistically significant higher frequency in women (OR 0.37; 95% CI 0.163-0.842; p=0.016), with increasing patient age (p=0.007), high-density lipoprotein (p=0.014) and platelet (p=0.008) levels, systemic immune inflammation index (p=0.018) and a decrease in the monocyte to high-density lipoprotein ratio (p=0.002). However, there was no statistically significant relationship between QTc interval prolongation, the number of concomitantly administered antipsychotics and their cumulative dose. Discussion. In addition to inhibition of potassium channels hERG (Kv11.1), clozapine can cause inflammatory damage to the myocardium and lead to its irreversible remodeling, diagnosed as myocarditis and dilated cardiomyopathy. However, despite the potentially fatal cardiotoxicity, clinical guidelines and instructions for the use of clozapine do not provide clear instructions on monitoring the electrocardiogram and possible predictors of life-threatening arrhythmias when taking this antipsychotic. Conclusion. Our study showed an increased risk of prolongation of the QTc interval in women, with increasing patient age, high-density lipoprotein and platelet levels, systemic immune inflammation index and a decrease in monocytes to high-density lipoproteins.

 

Keywords: QT prolongation, hematological inflammation indices, platelet, high density lipoproteins, schizophrenia, clozapine, electrocardiography.

 

Article (pdf)

 

Contacts

This email address is being protected from spambots. You need JavaScript enabled to view it.

 

Materials  

 

For citation: Kidyaeva A.V., Nasyrova R.F. Hematological inflammation coefficients as predictors of QT interval prolongation during clozapine therapy. Sibirskii Vestnik Psikhiatrii i Narkologii.2025; 2 (127): 62-69. https://doi.org/10.26617/1810-3111-2025-2(127)-62-69

 

REFERENCES

  1. Kidyaeva AV, Nasyrova RF. The role of cariprazine in the prevention and correction of antipsychotic-induced cardiometabolic disorders. Сurrent Therapy of Mental Disorders. 2024;3:51-57. https://doi.org/10.21265/PSYPH.2024.75.87.005 (in Russian).
  2. Selivanov GYu. Fundamentals of Psychiatry: a textbook. SPb.: St. Petersburg University of the State Fire Service of the Ministry of Emergency Situations of Russia named after Hero of the Russian Federation, General of the Army E.N. Zinichev, 2023:216 (in Russian).
  3. Nasyrova RF, Kidyaeva AV, Petrova MM, Shnayder NA. Antipsychotic-induced QT prolongation and Torsade de pointes in patients with mental disorders: A review. Safety and Risk of Pharmacotherapy. 2024;12(4):380-395. https://doi.org/10.30895/2312-7821-2024-410 (in Russian).
  4. Malin DI, Ryvkin PW, Bulatova DR. QT prolongation syndrome with antipsychotic and antidepressant drugs. Current Therapy of Mental Disorders. 2023;2:48-56. https://doi.org/10.21265/PSYPH.2023.69.57.006 (in Russian).
  5. Destere A, Merino D, Lavrut T, Rocher F, Viard D, Drici MD, Gérard AO. Drug-induced cardiac toxicity and adverse drug reactions, a narrative review. Therapie. 2024 Mar-Apr;79(2):161-172. https://doi.org/10.1016/j.therap.2023.10.008. Epub 2023 Oct 31. PMID: 37957054.
  6. Drug-induced long QT syndrome in psychiatry and neurology. RF Nasyrova, NG Neznanov, NA Schneider, MM. Petrova (ed.). St. Petersburg: DEAN Publishing House, 2024:592 (in Russian).
  7. Galkin SA, Kornetova EG, Mednova IA, Tiguntsev VV, Kornetov AN. Prevalence and risk factors for long qt interval syndrome in patients with schizo-phrenia during antipsychotic treatment. Current Therapy of Mental Disorders. 2024;2:32-39. https://doi.org/10.21265/PSYPH.2024.31.31.004 (in Russian).
  8. Kozlova SN. Comorbid cardiovascular pathology in military personnel with endogenous mental illnesses and neurotic disorders: dissertation abstract Cand. Sc. (Medicine). St. Petersburg, 2013:25(in Russian).
  9. Petrova NN. Modern psychiatry: from theory to practice. Personalized Psychiatry and Neurology. 2024;4(4):11-25.https://doi.org/10.52667/2712-9179-2024-4-4-11-25.
  10. KibitovAO, ShumskayaDS. Modern genome-wide association studies of mental disorders: focus on the mechanisms of inflammation. Siberian Herald of Psychiatry and Addiction Psychiatry. 2024;4(125):56-65.  https://doi.org/10.26617/1810-3111-2024-4(125)-56-65(in Russian).
  11. Popov MYu, Popov YuV, Kosterin DN, Lepik OV. Inflammatory hematological ratios in adolescents with mental disorders: a scoping review. Consortium Psychiatricum. 2024;5(2):45-61. https://doi.org/10.17816/CP15514 (in Russian).
  12. Nasyrova RF, Kidyaeva AV, Shnayder NA. Hematological predictors of antipsychotic-induced metabolic syndrome in a female patient with schizophrenia: Case report. Personalized Psychiatry and Neurology. 2024;4(2):39-46.https://doi.org/10.52667/2712-9179-2024-4-2-39-46.
  13. The ICD-10 classification of mental and behavioural disorders: clinical descriptions and diagnostic guidelines. Geneva: World Health Organization, 1992:362.
  14. Stanovaya VV, Guseynova ZT, Ivanov MV, Bigday EV. The phenomenon of therapeutic resistance in the treatment of schizophrenia: the possibilities of modern diagnostics and methods of antiresistant effects. V.M. Bekhterev Review of Psychiatry and Medical Psychology. 2023;57(4):120-130. https://doi.org/10.31363/2313-7053-2023-4-893 (in Russian).
  15. E14 Clinical evaluation of QT/QTc interval prolongation and proarrhythmic potential for non-antiarrhythmic drugs questions and answers (R3) Guidance for Industry. FDA; Silver Spring, MD : Center for Drug Evaluation and Research, 2017.
  16. Leucht S, Samara M, Heres S, Davis JM. Dose Equivalents for Antipsychotic Drugs: The DDD Method. Schizophr Bull. 2016 Jul;42 Suppl 1(Suppl 1):S90-4. https://doi.org/10.1093/schbul/sbv167. PMID: 27460622; PMCID: PMC4960429.
  17. Adetiloye AO, Abdelmottaleb W, Ahmed MF, Victoria AM, Ozbay MB, Valencia Manrique JC, Alaameri R, Badero O, Mushiyev S. Clozapine-induced myocarditis in a young man with refractory schizophrenia: Case report of a rare adverse event and review of the literature. Am J Case Rep. 2022 Jul 6;23:e936306. https://doi.org/10.12659/AJCR.936306. PMID: 35793273; PMCID: PMC9274917.
  18. Li XQ, Tang XR, Li LL. Antipsychotics cardiotoxicity: What's known and what's next. World J Psychiatry. 2021 Oct 19;11(10):736-753. https://doi.org/10.5498/wjp.v11.i10.736. PMID: 34733639; PMCID: PMC8546771.
  19. MalinDI, BulatovaDR, ShustovaLYu. Prolonged QT syndrome in patients with schizophrenia of a city psychiatric hospital. Social and Clinical Psychiatry. 2024;34(1):19-25 https://doi.org/10.34757/0869-4893.2024.34.1.002(in Russian).
  20. Khatib R, Sabir FRN, Omari C, Pepper C, Tayebjee MH. Managing drug-induced QT prolongation in clinical practice. Postgrad Med J. 2021 Jul;97(1149):452-458. https://doi.org/10.1136/postgradmedj-2020-138661. Epub 2020 Oct 29. PMID: 33122341; PMCID: PMC8237186.
  21. Vandael E, Vandenberk B, Vandenberghe J, Willems R, Foulon V. Risk factors for QTc-prolongation: systematic review of the evidence. Int J Clin Pharm. 2017 Feb;39(1):16-25. https://doi.org/10.1007/s11096-016-0414-2. Epub 2016 Dec 23. PMID: 28012118.
  22. Aronow WS, Shamliyan TA. Effects of atypical antipsychotic drugs on QT interval in patients with mental disorders. Ann Transl Med. 2018 Apr;6(8):147. https://doi.org/10.21037/atm.2018.03.17. PMID: 29862236; PMCID: PMC5952011.
  23. Luthra S, Duggan L, Agrawal A, Kaur G, Luthra N. Prevalence of high-dose antipsychotic prescribing in schizophrenia: A clinical audit in a regional Queensland mental health service. Int J Appl Basic Med Res. 2023 Apr-Jun;13(2):70-76. https://doi.org/10.4103/ijabmr.ijabmr_504_22. Epub 2023 Jul 17. PMID: 37614838; PMCID: PMC10443448.
  24. Beach SR, Celano CM, Sugrue AM, Adams C, Ackerman MJ, Noseworthy PA, Huffman JC. QT Prolongation, Torsades de Pointes, and Psychotropic Medications: A 5-Year Update. Psychosomatics. 2018 Mar-Apr;59(2):105-122. https://doi.org/10.1016/j.psym.2017.10.009. Epub 2017 Nov 3. PMID: 29275963.
  25. He L, Yu Y, Zhang L, He S, Yu W, Li L, Huang J, Li H. A real-world study of risk factors for QTc prolongation in schizophrenia patients receiving atypical antipsychotics. J Clin Psychopharmacol. 2022 Jan-Feb 01;42(1):71-74. https://doi.org/10.1097/JCP.0000000000001501. PMID: 34928562.
  26. Prestwood TR, Asgariroozbehani R, Wu S, Agarwal SM, Logan RW, Ballon JS, Hahn MK, Freyberg Z. Roles of inflammation in intrinsic pathophysiology and antipsychotic drug-induced metabolic disturbances of schizophrenia. Behav Brain Res. 2021 Mar 26;402:113101. https://doi.org/10.1016/j.bbr.2020.113101. Epub 2021 Jan 14. PMID: 33453341; PMCID: PMC7882027.
  27. Cordova VHS, Teixeira AD, Anzolin AP, Moschetta R, Belmonte-de-Abreu PS. Inflammatory markers in outpatients with schizophrenia diagnosis in regular use of clozapine: a cross-sectional study. Front Psychiatry. 2023 Oct 9;14:1269322. https://doi.org/10.3389/fpsyt.2023.1269322. PMID: 37876624; PMCID: PMC10591218.
  28. Seeman MV. The pharmacodynamics of antipsychotic drugs in women and men. Front Psychiatry. 2021 Apr 9;12:650904. https://doi.org/10.3389/fpsyt.2021.650904. PMID: 33897500; PMCID: PMC8062799.